^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MRTX1257

i
Other names: MRTX1257, MRTX-1257, MRTX 1257
Company:
BMS
Drug class:
KRAS inhibitor
1year
KRAS inhibition using MRTX1257: a novel radio-sensitizing partner. (PubMed, J Transl Med)
This work is the first to demonstrate in vitro as in vivo the radio-sensitizing effect of MRTX1257, a potent KRAS inhibitor compatible with oral administration, in CT26 KRAS mutated cell lines and tumors. This is a first step towards the use of new combinatorial strategies using KRAS inhibitors and RT in KRAS mutated tumors, which are the most represented in NSCLC with 14% of patients harboring this mutational profile.
Journal • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CD4 (CD4 Molecule) • CDK1 (Cyclin-dependent kinase 1)
|
PD-L1 expression • KRAS mutation • RAS mutation
|
Krazati (adagrasib) • MRTX1257
1year
Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition. (IMW 2023)
MRTX1257 predominantly reduced proliferation of XG7 cells, whereas MRTX1133 led to potent cell death induction of KARPAS620 and KP6 cells. Combinations of MRTX1257 with investigational or established anti-MM drugs, including melphalan, bortezomib or pomalidomide, led to no antagonism and in some cases – including combination with MEKi trametinib – caused supra-additive effects... This study documents mutant-specific activity of KRAS G12C and G12D inhibitors in MM cells and provides functional insights into the pharmacological inhibition of KRAS in MM. Ongoing in vitro and in vivo studies are examining the targeting of genes/pathways associated with escape from KRAS inhibition, as a framework for future efforts to improve the rates, depth and durability of responses to KRAS inhibition in MM.
Genomic study
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ETV5 (ETS Variant Transcription Factor 5) • DUSP6 (Dual specificity phosphatase 6) • ETV4 (ETS Variant Transcription Factor 4)
|
KRAS mutation • KRAS G12C • KRAS G12D • RAS mutation
|
Mekinist (trametinib) • bortezomib • pomalidomide • melphalan • MRTX1133 • MRTX1257
over1year
KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner (ESMO 2023)
Legal entity responsible for the study The authors. Expression of PD-L1 was reduced within tumor and myeloid cells, illustrating TME polarization towards a pro-inflammatory phenotype following the combination. Conclusions This work constitutes a first step towards new combinatorial approaches involving RT and MRTX1257 in KRAS G12C mutated cancers, with the aim of providing new therapeutic strategies.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CD4 (CD4 Molecule)
|
PD-L1 expression • KRAS mutation • KRAS wild-type
|
Krazati (adagrasib) • MRTX1257
over1year
Evaluation of KRAS inhibitor responses in novel murine KRAS lung cancer cell line models. (PubMed, Front Oncol)
The three lines exhibit similar in vitro sensitivities to KRAS inhibitors (MRTX-1257, MRTX-849, AMG-510), but distinct in vivo responses to MRTX-849 ranging from progressive growth with orthotopic LLC-NRAS KO tumors to modest shrinkage with mKRC.1 tumors. All three cell lines exhibited synergistic in vitro growth inhibition with combinations of MRTX-1257 and the SHP2/PTPN11 inhibitor, RMC-4550...Notably, single-agent MRTX-849 activity in mKRC.1 tumors and the combination response in LLC-NRAS KO tumors was lost when the experiments were performed in athymic nu/nu mice, supporting a growing literature demonstrating a role for adaptive immunity in the response to this class of drugs. These new models of murine KRAS mutant lung cancer should prove valuable for identifying improved therapeutic combination strategies with KRAS inhibitors.
Preclinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
|
KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12 • KRAS deletion
|
Lumakras (sotorasib) • Krazati (adagrasib) • MRTX1257 • RMC-4550
over2years
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. (PubMed, Cancer Res Commun)
FDA has recently granted approval to sotorasib for KRAS G12C mutated non-small cell lung cancer (NSCLC)...In this study, combining nuclear transport inhibitor selinexor with KRAS G12C inhibitors has resulted in potent antitumor effects in preclinical cancer models. This can be an effective combination therapy for cancer patients that do not respond or develop resistance to KRAS G12C inhibitor treatment.
Preclinical • Journal • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • XPO1 (Exportin 1)
|
KRAS mutation • KRAS expression
|
Lumakras (sotorasib) • Xpovio (selinexor) • Krazati (adagrasib) • MRTX1257
over2years
Patient-derived organoid drug responses corroborate known target-drug interactions for selected anticancer agents (AACR 2022)
The approved and investigational agents were selected to target specific genetic variants and pathways: KRAS G12C covalent inhibitors (sotorasib and MRTX-1257), RAS pathway inhibitors (BAY-293, BI-3406 and TNO-155), BRAF V600E/K inhibitors (dabrafenib and encorafenib), ABCB1 substrates (paclitaxel, doxorubicin, 5-FU, AZD-1775, and SN-38), and ABCB1 non-substrates (gemcitabine and trametinib)...This project was funded in part with federal funds from the NCI, NIH, under contract no. HHSN261201500003I.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
BRAF V600E • KRAS G12C • KRAS wild-type • BRAF V600K • RAS wild-type • ABCB1 expression
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • gemcitabine • paclitaxel • 5-fluorouracil • doxorubicin hydrochloride • Lumakras (sotorasib) • Braftovi (encorafenib) • adavosertib (AZD1775) • BI-3406 • batoprotafib (TNO155) • MRTX1257
over2years
RAS-pathway inhibitors (Sotorasib, MRTX-1257, TNO-155, BI-3406) in a Complex Spheroid Combination Screen with PDMR Cell Lines (AACR 2022)
The most successful combination was TNO-155 plus ipatasertib which resulted in more than 1-log of cell kill in 9 of 20 lines including the 5 KRAS G12C mutant lines. Venetoclax in combination with the RAS pathway inhibitors was active in 4 of the 5 KRAS G12C lines as was the combination of sapanisertib and TNO-155...This project was funded in part with federal funds from the NCI, NIH, under contract no. HHSN261200800001E.
Preclinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • RAS wild-type
|
Venclexta (venetoclax) • Lumakras (sotorasib) • sapanisertib (CB-228) • ipatasertib (RG7440) • BI-3406 • batoprotafib (TNO155) • MRTX1257
over3years
[VIRTUAL] Inhibition of nuclear transport protein XPO1 potentiates the effect of KRAS G12C inhibitors (AACR 2021)
In this study, we have tested two potent KRASG12C inhibitors, MRTX1257 and AMG510, on PDAC and NSCLC cell lines both as single agents and also in combination with nuclear transport inhibitor, Selinexor (KPT-330/XPOVIO). Cell growth inhibition was determined by MTT assay. In conclusion, we have demonstrated that the inhibitor of nuclear transport protein XPO1 has the ability to potentiate the anticancer activity of KRASG12C inhibitors in in vitro preclinical models of PDAC and NSCLC.
IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D
|
Lumakras (sotorasib) • Xpovio (selinexor) • MRTX1257
over3years
[VIRTUAL] Combination screening of KRASG12C specific inhibitors with other targeted therapies in patient-derived multicellular tumor spheroids (AACR 2021)
The pancreatic cancer cell line 323965-272-R-J2 carrying a KRASG12C variant exhibited an enhanced sensitivity to the combination of the mTOR inhibitor everolimus and a low concentration of either AMG-510 or MRTX-1257...Similarly, combining the mTOR kinase inhibitor sapanisertib, which blocks both mTORC1 and mTORC2 activities, with MTRX-1257 also led to a notable reduction in cell viability in all three KRASG12C-containing cell lines. In the KRASG12C variant melanoma cell line 299254-011-R-J1, targeting of the upstream receptor tyrosine kinase FGFR with erdafitinib in combination with the KRASG12C inhibitors produced greater than additive cell killing over the concentration range from 0.1 to 10 µM. Lastly, both KRASG12C inhibitors and abemaciclib, demonstrated additive to greater than additive cytotoxicity in the pancreatic cancer cell line 323965-272-R-J2, but this outcome was not observed with the CDK4/6 inhibitor, palbociclib, or in the other KRASG12C variant cell lines. These preclinical findings provide guidance regarding selection of combination regimens with KRASG12C inhibitors that may result in increased clinical efficacy.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • FGFR (Fibroblast Growth Factor Receptor)
|
KRAS mutation • KRAS G12C
|
Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Lumakras (sotorasib) • Balversa (erdafitinib) • sapanisertib (CB-228) • MRTX1257
almost4years
Validated HPLC-MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor in a small volume of mouse plasma and its application to a pharmacokinetic study in mice. (PubMed, Biomed Chromatogr)
AMG 510 and the IS (MRTX-1257) were extracted from mouse plasma using tert-butyl methyl ether and chromatographed using an isocratic mobile phase (0.2% formic acid:acetonitrile; 25:75, v/v) at a flow-rate of 0.65 mL/min on an Atlantis dC column. AMG 510 was demonstrated to be stable under the tested storage conditions. This novel method has been applied to a pharmacokinetic study in mice.
PK/PD data • Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
Lumakras (sotorasib) • MRTX1257
over4years
[VIRTUAL] Inhibiting adenosine signaling and KRAS enhances the effect of α-PD-1 therapy in a KRASG12C/TP53R172H/+ pancreatic cancer model (AACR-II 2020)
C57BL/6J mice bearing established KP4662-G12C (KRASG12C/TP53R172H/+) tumors (at least 150 mm3) were treated as indicated: A1421 (CD73i; 30 mg/kg/day, s.c.), anti-PD1 (Clone RMP 1-14; 10 mg/kg; twice per week, i.p), and MRTX-1257 (KRASi, 100 mg/kg/day, p.o.)... Here, we show that direct inhibition of mutant KRAS in pancreatic cancer models yields complex immunomodulatory effects. While antigen presentation pathways are transcriptionally upregulated and the expression of immunosuppressive chemokine is reduced, KRAS inhibition also reprograms nucleotide metabolism leading to elevated levels of ADO. These findings suggest that co-targeting mutant KRAS and adenosine signaling may enhance immunotherapy against pancreatic cancer and potentially other KRAS driven malignancies.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • CD73 (5'-Nucleotidase Ecto)
|
KRAS mutation • KRAS G12C • KRAS G12 • CD73 expression • KRAS expression
|
MRTX1257